These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11982685)

  • 21. Overactive bladder disease: the urge for better therapies.
    Thomas L; Culley EJ
    J Manag Care Pharm; 2008 May; 14(4):381-6. PubMed ID: 18500915
    [No Abstract]   [Full Text] [Related]  

  • 22. Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns.
    Novara G; Cornu JN
    Eur Urol; 2013 Feb; 63(2):306-8. PubMed ID: 23201469
    [No Abstract]   [Full Text] [Related]  

  • 23. Muscarinic receptor antagonists in the treatment of overactive bladder.
    Chapple CR
    Urology; 2000 May; 55(5A Suppl):33-46; discussion 50. PubMed ID: 10767450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.
    Swift S; Garely A; Dimpfl T; Payne C;
    Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolterodine: a safe and effective treatment for older patients with overactive bladder.
    Malone-Lee JG; Walsh JB; Maugourd MF
    J Am Geriatr Soc; 2001 Jun; 49(6):700-5. PubMed ID: 11454106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolterodine.
    Hills CJ; Winter SA; Balfour JA
    Drugs; 1998 Jun; 55(6):813-20; discussion 821-2. PubMed ID: 9617596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Schaefer W
    J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
    [No Abstract]   [Full Text] [Related]  

  • 29. The effects of reformulation: improved therapeutic index.
    MacDiarmid S; Sandage BW; Malhotra BK
    Curr Urol Rep; 2008 Nov; 9(6):465-71. PubMed ID: 18947511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary incontinence management: new questions from old assumptions.
    DuBeau CE
    J Am Geriatr Soc; 2001 Jun; 49(6):829-30. PubMed ID: 11454125
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of men with lower urinary tract symptoms and overactive bladder.
    Bell WA; Amarshi N
    JAMA; 2007 Mar; 297(11):1192; author reply 1193. PubMed ID: 17374810
    [No Abstract]   [Full Text] [Related]  

  • 32. Tolterodine for treatment of overactive bladder.
    Kanofsky JA; Nitti VW
    Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
    Athanasopoulos AA; Perimenis PS
    BJU Int; 2005 May; 95(7):1117-8. PubMed ID: 15839945
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
    Agarwal A; Dhiraaj S; Singhal V; Kapoor R; Tandon M
    Br J Anaesth; 2006 Mar; 96(3):377-80. PubMed ID: 16415311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolterodine: a review of its use in the treatment of overactive bladder.
    Clemett D; Jarvis B
    Drugs Aging; 2001; 18(4):277-304. PubMed ID: 11341475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy of the overactive bladder and advances in drug delivery.
    Cannon TW; Chancellor MB
    Clin Obstet Gynecol; 2002 Mar; 45(1):205-17. PubMed ID: 11862073
    [No Abstract]   [Full Text] [Related]  

  • 37. [More quality of life again with tolterodine].
    Praxis (Bern 1994); 2006 Oct; 95(42):1636. PubMed ID: 17111848
    [No Abstract]   [Full Text] [Related]  

  • 38. PHARMAC responds on tolterodine for overactive bladder.
    Moodie P
    N Z Med J; 2005 Feb; 119(1229):U1871. PubMed ID: 16498471
    [No Abstract]   [Full Text] [Related]  

  • 39. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
    Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solifenacin versus tolterodine--a head-to-head study: finally! But not final?
    Staskin DR; Dmochowski RR; Wein AJ
    Curr Urol Rep; 2005 Nov; 6(6):403-4. PubMed ID: 16238911
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.